A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability,
safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants
with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).